Popular Articles

Sciele Pharma Announces Availability Of Ulesfia (Benzyl Alcohol Lotion 5%), First Prescription Non-Neurotoxic Head Lice Treatment
Sciele Pharma, Inc., a Shionogi Company, announced the availability of Ulesfia (Benzyl Alcohol Lotion 5%), the first and only prescription medication that kills head lice by asphyxiation without potential neurotoxic side effects. Approved by the U.S. Food & Drug Administration (FDA), Ulesfia is indicated for the topical treatment of head lice infestation in patients 6 months of age and older. Ulesfia is available now by prescription nationwide in time for peak head lice season.
buy viagra
Lupus Foundation Of America Seeks Proposals For Research Studies On Childhood Lupus And Stem Cell Transplantation
The Lupus Foundation of America (LFA) is seeking proposals for grant funding for research studies on lupus, an unpredictable and potentially fatal autoimmune disease. Grants will support areas of study in pediatric lupus and adult stem cell transplantation. The purposes of the studies are to advance adult stem cell transplantation research in humans as a treatment for lupus and address key understanding of pediatric/adolescent lupus research issues.
News of the day
The Dioxin Poisoning Of Victor Yushchenko: Need For Methods In Routine Analysis Of Metabolites Of The Poison TCDD
An article published Online First exposes the facts of the poisoning of Ukrainian President Victor Yushchenko in 2004. It is the work of Professor Jean Saurat, from the Swiss Centre for Human Applied Toxicology, and the University Hospital, in Geneva, Switzerland, and his collaborators. It establishes that there is a need for routine analytical techniques to test for metabolites of TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) which is a type of dioxin and the poison that was used. This will help to provide proper treatment.
Medical Devices

Patient Notes - Clarity For Insurers And Doctors

Doctors will have greater clarity around releasing a patient"s full medical notes to insurance companies after the Privacy Commissioner concluded that the law allows insurers to collect only the information that they need to make insurance decisions. The Privacy Commissioner received a request from the New Zealand Medical Association (NZMA) to look into insurers" requests for full patient notes. The Commissioner concluded that insurance companies can only ask for patient notes that are of direct relevance to their decision to insure a person or to pay on a claim. "Medical practitioners should expect that the first request from an insurer will be of a more limited nature, such as questions about specific conditions," says NZMA GP Chair Dr Mark Peterson. "In some cases insurers may follow up by requesting more detailed information on a patient"s full notes for a specified period but both the insurer and the doctor will need to ensure that they have the patient"s permission to release additional information." Insurers have said they are willing to make their forms clearer - taking on board the Privacy Commissioner"s conclusions - so that if they intend to collect medical information there is no confusion for patients and doctors. The NZMA has produced a re for members, which reflects the results of the Commissioner"s inquiry. "If a doctor is uncertain whether a patient has authorised disclosure they need to discuss the matter with their patient," says Dr Peterson. "Patients may also want to see their medical notes before they make a decision on authorising disclosure." The Commissioner has said that occasionally an insurer will be entitled to collect full medical notes, if the more specific information does not provide the detail the insurer needs to make a decision. However, these situations should be rare. New Zealand Medical Association


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):